Serge Messerlian
InvestorOperating Partner, DCVC Bio at DCVC Bio · Board director at Auron Therapeutics · Board director at Plexium
San Francisco Bay Area
Find your path to Serge
374 people in our graph share verified history with Serge — schools, employers, funds. One of them is your warm intro.
KobeunlockedSerge: together at Johnson & Johnson (2016–2020)
×2Serge: together at Plexium
×2Serge: together at Auron Therapeutics
Serge: together at Johnson & Johnson
About
Serge Messerlian has worked across the life sciences industry in hematology, oncology, immunology, and rare diseases. He was CEO of Teon Therapeutics, an immuno-oncology biotech, and previously served as President of Janssen Oncology, a division of Johnson & Johnson, where he directed strategy for brands and pipeline programs including cell therapies and bi-specifics. He also held executive roles at Johnson & Johnson's Actelion, Baxalta, and Baxter International, and holds degrees from McGill University and an MBA from the University of Toronto.
Invests in
Biotech
Board director at Auron Therapeutics
Intro paths
→
In turn, Serge can intro founders to Auron Therapeutics's investors below.
Auron Therapeutics's investors · 3
Co-founders at Auron Therapeutics
KY
Katharine YenExecutive Officer, Director
KY
Kate YenFounder
Board director at Plexium
Intro paths
→
In turn, Serge can intro founders to Plexium's investors below.
Plexium's investors · 8
CRV (Charles River Ventures)Bay Area · $250K – $5M checks · since 2025DCVC (Data Collective)Palo Alto · $5M – $25M checks · since 2025M VenturesLos Angeles · $10.8M checks · since 2025Neotribe VenturesMenlo Park · $250K – $2M checks · since 2025Pivotal Life SciencesSan Francisco · since 2025SoftBank Vision FundLondon · since 2025TCG CrossoverPalo Alto · since 2025The Column GroupSan Francisco · $30M checks · since 2025
Experience
- PlexiumChief Executive Officercurrent2026 — present
- PlexiumMember Board of Directorscurrent2024 — present
- Auron Therapeutics, Inc.Member Board of Directorscurrent2024 — present
- DCVC Bio, Venture CapitalOperating Partnercurrent2024 — present
- Creyon BioChairman & CEO2024 — 2026
- Teon Therapeutics Inc.,Chief Executive Officer2022 — 2023
- Johnson & JohnsonPresident, Oncology2020 — 2022
- Johnson & JohnsonPresident, Actelion2017 — 2020
- Johnson & JohnsonSr. Director, US Portfolio Head, Immunology2016 — 2017
- BaxaltaVice President, Worldwide Portfolio Head, Biosimilars2013 — 2016
- Baxter International Inc.Vice President, Worldwide Portfolio Head, Hematology2012 — 2013
- Baxter International Inc.Sr. Director, Worldwide Portfolio Lead, Hematology2011 — 2012
- Baxter International Inc.Business Unit Director, BioScience2007 — 2011Canada
- Baxter International Inc.Business Unit Manager, BioScience2003 — 2007Canada
- Baxter International Inc.Technical Sales Specialist, BioScience1999 — 2003Canada
Skills & more
Strategy13Leadership5Strategic PlanningManagement1Biopharmaceuticals45Biotechnology37Market Access30Commercialization28Global Marketing24Product Launch20Sales Effectiveness18Pharmaceutical Sales12
+12 more
OncologyImmunologyCross-functional Team LeadershipRegulatory AffairsBiologicsClinical DevelopmentHematologyMedical AffairsHospital SalesVaccinesMarketing StrategyCommercial ManagementFrom Serge's professional profile.
Colleagues at DCVC Bio
Aimee Villamayor
Office Manager & Executive Assistant, DCVC Bio at DCVC Bio
Carly Smith
Office Assistant, DCVC Bio at DCVC Bio
Christopher Meldrum
Entrepreneur In Residence, DCVC Bio at DCVC Bio
Dr. Adil Anjem
Entrepreneur In Residence, DCVC Bio at DCVC Bio
Dr. Andy May
Operating Partner, DCVC Bio at DCVC Bio
Dr. Emily Park
Principal, DCVC Bio at DCVC Bio
Dr. John Hamer
Managing Partner, DCVC Bio at DCVC Bio
Dr. Justin Kern
Partner, DCVC Bio at DCVC Bio
Frequently asked questions
- Who is Serge Messerlian?
- Serge Messerlian has worked across the life sciences industry in hematology, oncology, immunology, and rare diseases. He was CEO of Teon Therapeutics, an immuno-oncology biotech, and previously served as President of Janssen Oncology, a division of Johnson & Johnson, where he directed strategy for brands and pipeline programs including cell therapies and bi-specifics. He also held executive roles at Johnson & Johnson's Actelion, Baxalta, and Baxter International, and holds degrees from McGill University and an MBA from the University of Toronto.
- Where does Serge Messerlian work?
- Serge Messerlian is Operating Partner, DCVC Bio at DCVC Bio and Board director at Auron Therapeutics and Board director at Plexium.
- What does Serge Messerlian invest in?
- Serge Messerlian invests in Biotech.
- Where did Serge Messerlian go to school?
- Serge Messerlian studied at University of Toronto - Rotman School of Management (Master of Business Administration - MBA); McGill University (Master of Science - MSc, Molecular Genetics); McGill University (Bachelor of Science - BSc, Physiology & Biotechnology).
Founder mafias
McGill University mafia207
Also came through, then founded or led a company.
Noubar AfeyanBSFounded ProFound Therapeutics +13Avak KahvejianB.Sc.Founded ProFound Therapeutics +5Jeffrey KarpBENGFounded Tissium +3Natalia BakaevaArtsFounded cashew +1Lauren GropperBachelor's degreeFounded Repurpose +1Jonathan LimMDFounded Boundless Bio +1
+ 200 more
Johnson & Johnson mafia71
Also came through, then founded or led a company.
Francisco LeonVice President & Head, Immunology Translational MedicineFounded Avalor Therapeutics +2Jacopo LeonardiDirector of MarketingFounded 4D Path +1Kim RodriguezDirector of SalesFounded BrainCheck +1Sid ViswanathanGlobal Operations Leadership DevelopmentFounded Alchemy Health +1Siyu HuangMarketing Leadership Development Program (MLDP)Founded Lionano +1Brian FaheyBusiness Development // Strategic InnovationFounded Niveus Medical +1
+ 64 more
University of Toronto - Rotman School of Management mafia37
Also came through, then founded or led a company.
Peter SumaICD.D from the Institute of Certified Directors at RotmanFounded Applied Brain Research +1Sahar SaidiMaster of Business Administration (MBA)Founded LUS Brands +1Ivan YuenMBAFounded WattpadMark SteeleMasters in Business AdministrationFounded Level AccessMike WinterfieldDirectors Education ProgramFounded Active Impact InvestmentsRay MuzykaICD.DFounded Bioware
+ 30 more
Auron Therapeutics mafia2
Also came through, then founded or led a company.
DCVC Bio mafia2
Also came through, then founded or led a company.
Same school
Also attended University of Toronto - Rotman School of Management194
Clayton MacDougaldInvestment Director - Water at Emerald Technology Ventures AgFrank FuInvestment Advisor at IOSG VenturesMary BoersmaPlatform Principal at American Family VenturesLeah MorrisExecutive Director, Encode: AI for Science at Pillar VCKaty Yam"The Indiana Jones of ideas" — a connector of people and ideasGreg AllenPartner at Chrysalix
+ 188 more
Also attended McGill University767
Harley FinkelsteinInvestor at Felicis VenturesMattias LjungmanInvestor at Moonfire VenturesNoubar AfeyanInvestor at Flagship PioneeringDavid NaultGeneral Partner at Luge CapitalLaviva MazharPrincipal at Luge CapitalLisa PurcellInvestor at Third Rock Ventures
+ 761 more
Shared employers
Also worked at Plexium16
Ian PeikonVenture Partner at Lux CapitalTherese LiechtensteinPartner at 4BIO CapitalKiersten SteadManaging Partner, DCVC Bio at DCVC (Data Collective)Rob HopfnerManaging Director at Pivotal Life SciencesBenjamin LiVice President at Pivotal Life SciencesJohn CassidyPartner, EMEA at SoftBank Vision Fund
+ 10 more
